bioCSL

Australia's CSL buys Novartis influenza vaccine unit for $275 million

Australia's CSL Ltd (CSL.AX), the world's largest blood products company, said on Monday it had agreed to buy Novartis AG's (NOVN.VX) global influenza vaccine business for $275 million.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics